$1.18
0.84%
Nasdaq, Nov 28, 10:00 pm CET
ISIN
US3741631036
Symbol
GERN

Geron Corporation Stock price

$1.18
-0.10 7.81% 1M
-0.27 18.62% 6M
-2.36 66.67% YTD
-2.99 71.70% 1Y
-1.11 48.47% 3Y
-0.69 36.73% 5Y
-3.92 76.86% 10Y
-7.38 86.21% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
-0.01 0.84%
ISIN
US3741631036
Symbol
GERN
Industry

Key metrics

Basic
Market capitalization
$753.3m
Enterprise Value
$492.0m
Net debt
positive
Cash
$380.5m
Shares outstanding
638.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.1 | 3.7
EV/Sales
2.7 | 2.4
EV/FCF
negative
P/B
3.0
Financial Health
Equity Ratio
47.2%
Return on Equity
-62.3%
ROCE
-13.6%
ROIC
-
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$183.4m | $205.0m
EBITDA
$-64.5m | $-81.0m
EBIT
$-65.0m | $-65.7m
Net Income
$-79.6m | $-79.9m
Free Cash Flow
$-132.9m
Growth (TTM | estimate)
Revenue
522.1% | 166.2%
EBITDA
68.8% | 53.2%
EBIT
68.6% | 62.2%
Net Income
60.3% | 54.2%
Free Cash Flow
38.7%
Margin (TTM | estimate)
Gross
97.7%
EBITDA
-35.2% | -39.5%
EBIT
-35.5%
Net
-43.4% | -39.0%
Free Cash Flow
-72.5%
More
EPS
$-0.1
FCF per Share
$-0.2
Short interest
12.7%
Employees
229
Rev per Employee
$340.0k
Show more

Is Geron Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Geron Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Geron Corporation forecast:

11x Buy
73%
3x Hold
20%
1x Sell
7%

Analyst Opinions

15 Analysts have issued a Geron Corporation forecast:

Buy
73%
Hold
20%
Sell
7%

Financial data from Geron Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
183 183
522% 522%
100%
- Direct Costs 4.22 4.22
779% 779%
2%
179 179
525% 525%
98%
- Selling and Administrative Expenses 161 161
30% 30%
88%
- Research and Development Expense 81 81
28% 28%
44%
-65 -65
69% 69%
-35%
- Depreciation and Amortization 0.54 0.54
6% 6%
0%
EBIT (Operating Income) EBIT -65 -65
69% 69%
-35%
Net Profit -80 -80
60% 60%
-43%

In millions USD.

Don't miss a Thing! We will send you all news about Geron Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Geron Corporation Stock News

Positive
Seeking Alpha
22 days ago
Geron reported Q3'25 Rytelo revenues of $47.2M, down from $49M in Q2, with no underlying increase in demand reported. Despite efforts to boost Rytelo's use in first and second-line therapy (now 36%, up from 30%), revenue growth remains elusive for GERN. Recent leadership changes include the departure of COO Andrew Grethlein and CCO Jim Ziegler, with Ahmed ElNawawi stepping in as CCO.
Neutral
Seeking Alpha
24 days ago
Geron Corporation ( GERN ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Dawn Schottlandt - Senior Vice President of Investor Relations & Corporate Affairs Harout Semerjian - CEO, President & Director Joseph Eid - Executive VP of Research & Development and Chief Medical Officer Michelle Robertson - Executive VP, CFO, Treasurer and Principal Financial & Accounting Offic...
Neutral
Business Wire
24 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2025 and recent business highlights. "The high unmet need in lower-risk MDS is well known, and RYTELO is a therapy with a novel mechanism of action and the pot...
More Geron Corporation News

Company Profile

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Head office United States
CEO Dawn Bir
Employees 229
Founded 1990
Website www.geron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today